Gilead: Three HIV Launches Expected In Near-Term Future
This article was originally published in The Pink Sheet Daily
Executive Summary
Sales are strong, especially for Stribild, but Gilead is planning ahead for the patent expiration of Viread and replacing it in combo regimens with a new formulation of tenofovir that offers enhanced therapeutic benefits.